SAN DIEGO, March 22 /PRNewswire-FirstCall/ -- Gen-Probe
Incorporated (Nasdaq: GPRO) announced today that Brian McNamee, MBBS, CEO and managing director
of the leading international biopharmaceutical company CSL Ltd.,
has been elected to its board of directors. Gen-Probe's board
now has nine members, including seven independent directors.
"We are delighted that Brian has agreed to re-join Gen-Probe's
already strong board," said Hank
Nordhoff, the Company's chairman. "We are sure to
benefit from his experiences leading a multi-billion-dollar
company, and from his broad industry knowledge and international
perspective."
Dr. McNamee, 53, served on Gen-Probe's board from the time of
the Company's September, 2002 spin-off from Chugai until May, 2007.
He has served as CEO and managing director of CSL since 1990.
CSL has a combined heritage of outstanding contributions to
medicine and human health, with more than 90 years experience in
the development and manufacture of vaccines and plasma protein
biotherapies. Dr. McNamee obtained his medical degree from
the University of Melbourne.
About Gen-Probe
Gen-Probe Incorporated is a global leader in the development,
manufacture and marketing of rapid, accurate and cost-effective
molecular diagnostic products and services that are used primarily
to diagnose human diseases, screen donated human blood, and ensure
transplant compatibility. Gen-Probe has approximately 27
years of NAT expertise, and received the 2004 National Medal of
Technology, America's highest honor for technological innovation,
for developing NAT assays for blood screening. Gen-Probe is
headquartered in San Diego and
employs approximately 1,300 people. For more information, go to
www.gen-probe.com.
Caution Regarding Forward-Looking Statements
Any statements in this press release about our expectations,
beliefs, plans, objectives, assumptions, future events or
performance are not historical facts and are forward-looking
statements. These statements are often, but not always, made
through the use of words or phrases such as believe, will, expect,
anticipate, estimate, intend, plan and would. Forward-looking
statements are not guarantees of performance. They involve known
and unknown risks, uncertainties and assumptions that may cause
actual results to differ materially from those expressed or
implied. Some of the risks, uncertainties and assumptions
that could cause actual results to differ materially from estimates
or projections in the forward-looking statement include, but are
not limited to, the risk that Gen-Probe may not be able to retain
its key employees and directors. For additional information about
risks and uncertainties we face and a discussion of our financial
statements and footnotes, see documents we have filed with the SEC,
including our Report on Form 10-K for the fiscal year ended
December 31, 2009, and all our
periodic filings made with the SEC. We assume no obligation
and expressly disclaim any duty to update any forward-looking
statement to reflect events or circumstances after the date of this
press release or to reflect the occurrence of subsequent
events.
|
|
Contact:
|
|
Michael
Watts
Vice president, investor relations and
corporate communications
858-410-8673
|
|
|
|
|
|
|
SOURCE Gen-Probe Incorporated